XANTHOMAS

Czech version

Authors: A. Žák
Authors‘ workplace: IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze, přednosta prof. MUDr. Radan Brůha, CSc.
Published in: Čes-slov Derm, 97, 2022, No. 6, p. 231-246
Category: Reviews (Continuing Medical Education)

Overview

Xanthomas are clusters of foam cells located in connective tissue. They arise from the transformation of macrophages which take up oxidatively modified lipoproteins, especially LDL (ox-LDL), by means of specific ("scavenger") receptors. Another mechanism of foam cell formation is phagocytosis of LDL aggregates or LDL complexes with antibodies. The origin of xanthomas is similar to the development of the early stage of an atherosclerotic lesion. Tendon and tuberous xanthomas are specific for autosomal dominant familial hypercholesterolemia (FH). Eruptive xanthomas are a skin manifestation of severe hypertriglyceridemia and signal the risk of acute pancreatitis and the manifestation of diabetes. Xanthoma striatum palmare is a pathognomonic manifestation of primary dys-β-lipoproteinemia. Tendon and tuberous xanthomas are further specific for rare disorders such as cerebrotendinous xanthomatosis and familial β-sitosterolemia. Increased concentrations of LDL-cholesterol, or phytosterols (in sitosterolemia) and cholestanol (in cerebrotendinous xanthomatosis), and their depositions in tissues are associated with the development of xanthomas, atheromatous plaques and premature atherosclerosis. Xanthelasma palpebrarum, until recently considered as a cosmetic lesion, is associated with a 15-year reduction in the average life expectancy by 15 years, increases the risk of atherosclerotic cardiovascular diseases by more than 40%, and is also often associated with non-alcoholic steatosis of the liver. The presence of tendon xanthomas in patients with FH which was proven by molecular biological methods increased the risk of cardiovascular disease 2–4 times compared to individuals with FH without tendon xanthomas. Necrobiotic xanthogranuloma, diffuse plane xanthomas and normolipidemic xanthomas are often associated with paraproteinemia and lymphoproliferative disorders.

Keywords:

inflammation – dyslipidemia – xanthoma – cardiovascular risk – oxidatively modified low-density lipoproteins – foam cells

Sources

1. ABATE, M., SCHIAVONE, C., SALINI, V. et al. Occurrence of tendon pathologies in metabolic disease. Rheumatology, 2013, 52(4), p. 599–608.

2. ADAM, Z., VESELÝ, I., MOTYČKOVÁ, I. et al. Oční víčka se žlutými granulomy – periokulární xantogranulom dospělých spojený s astmatem. Popis případu a přehled klinických forem juvenilního xantogranulomu a terapie. Vnitř. Lék., 2012, 58(5), s. 365–367.

3. AKYÜZ, A. R., TURAN, T., ERKUS¸ M. E. et al. Xanthelasma palpebrarum associated with increased cardio-ankle vascular index in asymptomatic subjects. Wien Klin Wochenschr., 2016, 128(Suppl. 8), p. S610–S613.

4. ARTIEDA, M., CENARRO, A., JUNQUERA, C. et al. Tendon xanthomas in familial hypercholesterolemia are associated with differential inflammatory response of macrophages to oxidized LDL. FEBS Lett., 2005, 579(20), p. 4503–4512.

5. BALLANTYNE, C. M. Clinical Lipidology. A Companion to Braunwald´s Heart Disease. 2nd Ed. Philadelphia: Elsevier Saunders, 2015, 550 p. ISBN 978-0- 323-28786-9.

6. BERGMAN, R. The pathogenesis and clinical significance of xanthelasma palpebrarum. Int. J. Dermatol., 1994, 30(2 Pt 1), p. 236–242.

7. BREWER, H. B., Jr. High-density lipoprotein metabolism. In: Clinical Lipidology. A Companion to Braunwald ´s Heart Disease. Ballantyne, C. M. Ed. 2nd Ed. Philadelphia: Elsevier Saunders, 2015, p. 43–52.

8. CAVALLAZZI, R., HIRANI, A., VASU, T. S. et al. Clinical manifestation and treatment of adult-onset asthma and periocular xanthogranuloma. Can Respir J., 2009, 16(5), p. 159–162.

9. CIVEIRA, F., CASTILLO, S., ALONSO, R. et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutations. Arterioscler Thromb Vasc Biol., 2005, 25(9), p. 1960–1965.

10. CIVEIRA, F., PEREZ-CALAHORRA, S., MATEO-GALLEGO, R. Rapid resolution of xanthelasmas after treatment with alirocumab. J Clin Lipidol., 2016, 10(5), p. 1259–1261.

11. DURINGTON, P., SNIDERMAN, A. Hyperlipidemia. 2nd Ed. Oxford: Health Press 2002. 144 p. ISBN 1-903734-23-1.

12. FLORIÁNKOVÁ, M., URBANOVÁ, Z., BLÁHOVÁ, Š. et al. Sitosterolémie: klinická, biochemická a molekulárně genetická charakteristika 3letého chlapce s významnou hypercholesterolémií. Čes-slov Pediat., 2017, 72(8), s. 495–503.

13. GHOSH, Y. K., PRADHAN, E., AHLUWALIA, H. S. Excision of xanthelasmata – clamp, shave, and suture. Int J Dermatol., 2009, 48(2), p. 181–183.

14. HARADA, T., INAGAKI-TANIMURA, M, NAGAOU, M. et al. Frequency of Achilles tendon xanthoma in patients with acute coronary syndrome. J Atheroscler Thromb., 2017, 24(9), p. 949–953.

15. HARADA-SHIBA, M., AKO, J., ARAI, H. et al. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLOPRE-J study. Atherosclerosis, 2018, 277, p. 362–368.

16. HARRIS, R. S., JR, HUGH, R., GILMORE III, H. R., BRICKER, L. A. et al. Long-Term Oral Administration of Probucol [4, 4‘-(Isopropylidenedithio) bis (2, 6-di-t-Butylphenol)] (DH-581) in the Management of Hypercholesterolemia. J Am Geriatr Soc., 1974, 22(4), p. 166–175.

17. HASHIMOTO, T., MINAMI, Y., KAKIZAKI, R. et al. Achilles tendon thickening is associated with disease severity and plaque vulnerability in patient with coronary artery disease. J Clin Lipidol., 2019, 13(1), p. 194–200.

18. HIRATA, Y., OKAWA, K., IKEDA, M. et al. Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells. J Dermatol Sci., 2002, 30(3), p. 248–255.

19. HUSSAIN, I., GARG, A. Lipodystrophy Syndromes. Endocrinol Metab Clin North Am., 2016, 45(4), p. 783– 797.

20. CHANG, H.-C., SUNG, C.-W., LIN, M. H. Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis. J Am Acad Dermatol., 2020, 82(3), p. 596–605.

21. CHEN, H.-W., LIN, J.-C., WU, Y.-H. et al. Risk of non-alcoholic fatty liver disease in xanthelasma palpebrarum. J Inflamm Res., 2021, 14, p. 1891–1899.

22. CHRISTOFFERSEN, M., FRIKKE-SCHMIDT, R., SCHNOUT, P. et al. Xanthelasmata, arcus lipoides cornae, and ischaemic vascular disease and death in general population: prospective cohort study. BMJ., 2011, 343, d5497.

23. CHRISTOFFERSEN, M., TYBJÆRG-HANSEN, A. Visible aging signs as risk markers for ischemic heart disease: Philadelphia: Epidemiology, pathogenesis and clinical implications. Ageing Res Rev., 2016, 25, p. 24–41.

24. JAMESON, J. L. Harrison´s Principles of Internal Medicine. 20th Ed. Ohio, United States, McGraw-Hill Education, 2018, 4048 p. ISBN 1259644030.

25. JEZIORSKA, M., HASSAN, A., MACKNESS, M, I. et al. Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis. J Clin Pathol., 2003, 56(1), p. 64–68.

26. JUNYENT, M., GILABERT, R., ZAMBÓN. D. et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscl Thromb Vasc Biol., 2005, 25(10), p. 2203–2208.

27. KAJINAMI, K., NISHITSUJI, M., TAKEDA, Y. et al. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Atherosclerosis, 1996, 120(1-2), p. 181–187.

28. KHODE, S., TAN, S. H. T., TAN, E-P. A. Xanthelasma palpebrarum: More than meets the eye. Indian J Otolaryngol Head Neck Surg., 2019, 71(Suppl. 1), p. S439–S446.

29. KIM, J., KIM, Y. J., LIM, H., LEE, S. I. Bilateral circular xanthelasma palpebrarum. Arch Plast Surg., 2012, 39(4), p. 435–437.

30. KITAHARA, H., MORI, N., SAITO, Y. et al. Prevalence of Achilles tendon xanthoma and familial hypercholesterolemia in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart and Vessels, 2019, 34(10), p. 1595– 1899.

31. KITAHARA, H., NAKAYAMA, T., FUJIMOTO, Y. et al. Association between Achilles tendon xanthoma and severity of coronary artery disease in patients undergoing percutaneous coronary intervention. J Cardiol., 2020, 75(6), p. 654–658.

32. KOUMAR, V., ABBAS, A. K., FAUSTO, N. et al. Cellular response to stress and toxic insult: adaptation, injury, and death. In: Pathologic basis of disease. 8th ed. Philadelphia: Saunders Elsevier, 2010, p. 3–42.

33. LADIZINSKI, B., LEE, K. C. Eruptive xanthomas in a patient with severe hypertriglyceridemia and type 2 diabetes. CMAJ., 2013, 185(18), p. 1600.

34. LAFTAH, Z., AL-NIAIMI, F. Xanthelasma: An update on treatment modalities. J Cutan Aesthet Surg., 2018, 11(1), p. 1–6.

35. LAKEY, W. C., GREYSHOCK, N., GUYTON, J. R. Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants. J Clin Lipidol., 2013, 7(2), p. 178–181.

36. LEAF, D. A. Chylomicronemia and chylomicronemia syndrome: a practical approach to management. Am J Med., 2008, 121(1), p. 10–12.

37. MACH, F., BAIGENT, C., CATAPANO, A. L. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, p. 140–205.

38. MACHADO, P. V., DAXBACHER, E. L., OBADIA, D. L. et al. Do you know this syndrome? Berardinelli-Seip syndrome. Ann Bras Dermatol., 2013, 88(6), p. 1011–1013.

39. MARAIS, A. D. Apolipoprotein E and Atherosclerosis. Curr Atheroscler Rep., 2021, 23(7), p. 34.

40. MATSUURA, F., HIRANO, K., KOSEKI, M. et al. Familial massive tendon xanthomatosis with decreased high-density lipoprotein-mediated cholesterol efflux. Metabolism, 2005, 54(8), p. 1095–1101.

41. MEHTA, A., SHAPIRO, M. D. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol., 2022, 19(3), p. 168–179.

42. MENOTTI, A., PUDDU, P. E., LANTI, M. et al. Cardiovascular risk factors predict survival in middle-aged men during 50 years. Eur J Intern Med., 2013, 24(1), p. 67–74.

43. MILLER, Y. I., TSIMIKAS, S. Lipoprotein oxidation: Mechanisms and Biotheranostic Applications. In: Clinical Lipidology. A Companion to Braunwald´s Heart Disease. Ballantyne, C. M., Ed. 2nd Ed. Philadelphia: Elsevier Saunders, 2015, p. 78–89.

44. MOTAZACKER, M. M., KASTELEIN, J., KUIVENHOVEN, L. A. Impact of rare and common genetic variants on lipoprotein metabolism. In: Clinical Lipidology. A Companion to Braunwald´s Heart Disease. Ballantyne, C. M., Ed. 2nd Ed. Philadelphia: Elsevier Saunders, 2015, p. 68–77.

45. NAIR, P. A., SINGHAL, R. Xanthelasma palpebrarum – a brief review. Clin Cosmet Investig Dermatol., 2017, 11, p. 1–5.

46. NELSON, C., A., ZHONG, C. S., HASHEMI, D. A. et al. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. JAMA Dermatol., 2020, 156(3), p. 270–279.

47. NIE, S., CHEN, G., CAO, X. et al. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis., 2014, 9, p. 179.

48. NOËL, B. Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol., 2007, 21(9), p. 1244–1248.

49. OHTAKI, S., ASHIDA, K., MATSUO, Y. et al. Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia. Clin Case Rep., 2022, 10, e05671.

50. OOSTERVEER, D. M., VERSMISSEN, J., YAZDANPANAH, M. et al. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia. Atherosclerosis, 2009, 206(1), p. 223–227.

51. OOSTERVEER, D. M., VERMISSEN, J., YAZDANPANAH, M., HAMZA, T. H. Differences in characteristic and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and metaanalysis. Atherosclerosis, 2009, 207(2), p. 311–317.

52. PANDHI, D., GUPTA, P., SINGAL, A. et al. Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J., 2012, 88(1038), p. 198–204.

53. PHATLHANE, D. V., ZEMLIN, A. E. Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis. Ann Hepatol., 2015, 14(6), p. 924– 928.

54. RAMASAMY, I. Update on the molecular biology of dyslipidemias. Clinica Chimica Acta, 2016, 454, p. 143–185.

55. ROHITH, G., RAJESH, B. S., KEERTHI A. R. et al. Hypertriglyceridaemic pancreatitis with eruptive xanthomas. BMJ Case Rep., 2021, 14(7), e241970.

56. SANDHU, S., AL-SARRAF, A., TARABOANTA, C. et al. Incidence of pancreatitis, secondary cause, and treatment of patients referred to special lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis., 2011, 10, p. 157.

57. SAYIN, I., AYLI, M., OĞUZ, A. K., Seval G. C. Xanthelasma palpebrarum: a new side effect of nilotinib. BMJ Case Rep., 2016, 2016, bcr2015213511.

58. SIVAK-CALLCOTT, J. A., ROOTMAN, J., RASMUSSEN, S. L. et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol., 2006, 90(5), p. 602–608.

59. SOLAK, B., KARA, R. O., ACIKGOZ S., B. et al. First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep., 2015, 2015, bcr2015212160.

60. STARK, M., STUART, J. Eruptive xanthoma in the setting of hypertriglyceridemia. Am J Emerg Med., 2018, 36(8), p. 1524e5–1524e7.

61. SUZUKI, L., HIRAYAMA, S., FUKUI, M. et al. Lipoprotein- X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages. J Clin Lipidol., 2017, 11(1), p. 110–118.

62. SZALAT, R., ARNULF, B., KARLIN, L. et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood, 2011, 118(14), p. 3777–3784.

63. ŠOBRA, J. Vrozené poruchy metabolismu lipoproteinů. In: Hyánek, J. ed. Klinické a biochemické aspekty vrozených metabolických vad. Praha: Avicenum, 1980, p. 200–240.

64. ŠTORK, J. Kožní projevy z poruch metabolismu a nutrice. In: Štork, J., Arenberger, P., Pizinger, K., Semrádová, V., Vosmík, F. ed. Dermatologie. Praha: Galén, Karolinum, 2008, p. 259–274.

65. TADA, H., NOHARA, A., INAZU, A. et al. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb., 2018, 25(9), p. 783– 789.

66. THOMPSON, G. R. A handbook of hyperlipidemia. London: MSD, Merk Sharp & Dohme, Current Science Ltd., 1990, 236 p. ISBN 1-870485-16-5.

67. TÖRÖK, L. Kožní projevy při chorobách vnitřních orgánů. Praha: Česká lékařská společnost J. E. Purkyně, 1998. 228 s. ISBN 3-335-00593-7.

68. TSOULI, S. G., KIORTSIS, D. N., ARGYROPOULOU, M. I. et al. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest., 2005, 35(4), p. 236–244.

69. TSOULI, S. G., XYDIS, V., ARGYROPOULOU, M. I. et al. Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: An ultrasonographic study. Atherosclerosis, 2009, 205, p. 151–155.

70. VANGARA, S. S., KLINGBEIL, K. D., FERTIG, R. M. et al. Severe hypertriglyceridemia presenting as eruptive xanthomatosis. J Family Med Prim Care, 2018, 7(1), p. 267–270.

71. WANG, B., ZHANG, Q., PAN, L.-L. et al. Association of Achilles tendon thickness and LDL-cholesterol levels in patients with hypercholesterolemia. Lipids Health Dis., 2018, 17(1), p. 131.

72. WANG, K. Y., HSU, K. C., LIU, W. C. et al. Relationship between xanthelasma palpebrarum and hyperlipidemia. Ann Plast Surg., 2018, 80(2S Suppl. 1), p. S84–S86.

73. WEN, Y., LEAKE, D. S. Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res., 2007, 100(9), p. 1337–1343.

74. WINKLER, J. K., HOFFMANN, J., ENK, A. et al. Diffuse plane Xanthome bei Mycosis fungoides. Hautartz, 2019, 70(6), p. 438–442.

75. WOLLINA, U., KOCH, A., HANSEL, G. et al. Eruptive xanthomas – Two case reports with distinct features. Maced J Med Sci., 2018, 6(11), p. 2152– 2154.

76. XU, S., OGURA, S., CHEN, J. et al. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci., 2013, 70(16), p. 2859– 2872.

77. ZAHRADOVÁ, L., ADAM, Z., FEIT, J. et al. Nekrobiotický xantogranulom – vzácná kožní komplikace u nemocného s mnohočetným myelomem. Vnitř Lék., 2010, 56(Suppl. 2), p. 2S179–2S182.

78. ZAKON, S. J., OYAMADA, A., ROSENTHAL, I. H. Eruptive xanthoma and hyperlipemia in glycogen storage disease (von Gierke‘s disease). AMA Arch Derm Syphilol., 1953, 67(2), p. 146–151.

79. ZEMAN, M., ŽÁK, A., HERDOVÁ, J. Analýza plazmatických lipidů a klinická charakteristika pacientů s nálezem xanthelasma palpebrarum. Čas Lék čes., 1981, 120(26), p. 806–808.

80. ŽÁK, A., ZEMAN, M., SLABY, A. et al. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc, 2014, 158(2), p. 181–188.

Labels

Dermatology & STDs Paediatric dermatology & STDs

KONTROLNÍ TEST

Hypertrophic Plaques in the Axillae

Dermatoscopy in "Atypical" Locations – Flat Pigmented Lesions on the Face

Zápis ze schůze výboru ČDS konané dne 20. 10. 2022

Poznatky z kongresu EADV v Miláně 7.–10. 9. 2022

Profesor MUDr. Karel Pizinger, CSc. – 70

Odborné akce 2023

Article was published in

Czech-Slovak Dermatology

2022 Issue 6